Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of AZD9977 Formulations and Food Effect in Healthy Males
NCT03450759Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of balcinrenone in heart failure (HF) and chronic kidney disease (CKD) (4 arms), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration-time curve from time zero to infinity at Day 7, Area under the plasma concentration-curve from time zero to time of last quantifiable concentration at Day 7 and 2 more. Started Mar 2018; status: completed.
02
Drugs
balcinrenone
03
Conditions
heart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03450759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03450759.